Dimethyltryptamine is an endogenous compound that acts as an agonist for the sigma-1 receptor.
In short: Known for its rapid onset and intense, dream-like visual displays, dimethyltryptamine (DMT) is a potent psychedelic found naturally in many plants and animals. While often studied for its hallucinogenic properties, recent research identifies it as an endogenous regulator of the sigma-1 receptor, a protein distributed throughout the human body.
Dimethyltryptamine, or DMT, is a serotonergic hallucinogen that has been synthesized since 1931. Structurally related to neurotransmitters like serotonin and melatonin, it interacts with various receptors, most notably 5-HT2A, 5-HT1A, and 5-HT2C. Beyond these serotonin pathways, DMT functions as an endogenous agonist for the sigma-1 receptor. This receptor, once misidentified as an opioid receptor, is now understood to be an orphan receptor that influences voltage-gated sodium ion channels in cardiac myocytes and other cells.
The subjective experience of DMT is characterized by its extreme intensity and brief duration. When administered intravenously, psychological effects begin almost immediately, peaking within 90 to 120 seconds and resolving within 30 minutes. Users often report a vivid, brightly colored visual display and a state of ego dissolution or loss of control. Because of this rapid time course, it was colloquially dubbed the businessman's trip in the 1960s, as it allowed for a full psychedelic experience in a fraction of the time required by substances like LSD.
DMT is not orally active on its own because the enzyme monoamine oxidase A (MAO-A) rapidly metabolizes it in the gut. However, when combined with a monoamine oxidase inhibitor (MAOI)—such as the harmala alkaloids found in the Banisteriopsis caapi vine used in traditional ayahuasca brews—the drug becomes orally active and its effects are significantly extended. While DMT is internationally illegal, its unique pharmacology has made it a subject of ongoing clinical trials for conditions like treatment-resistant depression, as researchers explore its potential as a scalable alternative to longer-acting psychedelics.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Dose-Response Study of N,N-Dimethyltryptamine in Humans
- Also: Dimethyltryptamine
- Also: The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
To cite this card, link to https://intellectplus.co.uk/app/science-dimethyltryptamine.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Human body & genes · More in Science · Latest · A–Z · All topics